Top Markets
Coin of the day
9 Meters Biopharma, Inc. 9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc.

NMTR
Classifica tra le azioni #40887
Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a... Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. Its core mission is to innovate treatments for individuals suffering from rare digestive conditions, gastrointestinal disorders with inadequate therapeutic options, and other severe debilitating ailments. The company's pipeline features several promising drug candidates. Larazotide, an 8-amino acid peptide, is currently in a Phase 3 clinical trial for the treatment of celiac disease and is also being assessed in a Phase IIa study for multi-system inflammatory syndrome. Another key asset, Vurolenatide, a long-acting injectable glucagon-like peptide-1, is undergoing Phase 2 clinical trials to address short bowel syndrome. Additionally, 9 Meters Biopharma is advancing other compounds, including NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended for the prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody designed to target specific obesity disorders; and NM-004, a double-cleaved mesalamine combined with an immunomodulator, slated for rare and/or orphan indications.
Prezzo delle azioni
$0.0169
Ultima sincronizzazione: 2023-08-21
Capitalizzazione di mercato
$66.40K
Variazione (1 giorno)
4.32%
Variazione (1 anno)
0.00%
Paese
US
Scambia 9 Meters Biopharma, Inc. (NMTR)

Categoria

Utile per 9 Meters Biopharma, Inc. (NMTR)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di 9 Meters Biopharma, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di 9 Meters Biopharma, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE